Cliff Asness’s Apogee Therapeutics APGE Stock Holding History

Cliff Asness’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Sell	7,958 -69	-0.9%	-$6.22K	﹤0.01%	2973
2026 Q1	$676K	Buy	+8,027	New	+$583K	﹤0.01%	2979
2025 Q1	–	Sell	-5,365	Closed	-$243K	–	3154
2024 Q4	$243K	Buy	+5,365	New	+$274K	﹤0.01%	2591
2024 Q3	–	Sell	-11,535	Closed	-$454K	–	2762
2024 Q2	$454K	Buy	+11,535	New	+$560K	﹤0.01%	2089

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Cliff Asness's APGE Position: Q2 2026 in Review

Cliff Asness reduced its Apogee Therapeutics (APGE) stake by 0.86% in Q2 2026, selling an estimated $6.22K and leaving 7,958 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2973.

Cliff Asness first reported a position in APGE in Q2 2024 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Cliff Asness held 7,958 shares of Apogee Therapeutics worth $1.06M as of Q2 2026.
Cliff Asness sold 69 Apogee Therapeutics shares in Q2 2026, an estimated $6.22K.
Apogee Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2973 holding.
Cliff Asness first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 4 quarters since.
285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.